Bryan T J Hennessy

Summary

Publications

  1. pmc OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets
    Stephen F Madden
    Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
    Mol Cancer 13:241. 2014
  2. pmc A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation
    Kimberly C Wiegand
    Department of Surgical Oncology, British Columbia, Cancer Agency, Vancouver, BC, Canada
    BMC Cancer 14:120. 2014
  3. pmc Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
    M S N Mohd Sharial
    Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland
    Ann Oncol 23:3007-16. 2012
  4. pmc An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays
    Huifang Guo
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Proteome Sci 10:56. 2012
  5. pmc Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
  6. pmc Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
    Chad J Creighton
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Breast Cancer Res 12:R40. 2010
  7. pmc Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer
    Bryan T J Hennessy
    Department of Gynecology Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:3570-6. 2010
  8. pmc c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer
    Pablo Vivas-Mejia
    Department of Experimental Therapeutics, Center for RNAi and non coding RNA, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:184-94. 2010

Collaborators

  • L Rubin
  • Mark S Carey
  • Jie Li
  • Russell R Broaddus
  • Yang Li
  • Maurie Markman
  • Ariel Fernandez
  • Karen H Lu
  • Gordon B Mills
  • Zhenlin Ju
  • Kimberly C Wiegand
  • Stephen F Madden
  • Yiling Lu
  • M S N Mohd Sharial
  • Huifang Guo
  • Wenbin Liu
  • Ana M Gonzalez-Angulo
  • Ana Lluch
  • Pablo Vivas-Mejia
  • Chad J Creighton
  • Katherine Stemke-Hale
  • Mollianne McGahren
  • David G Huntsman
  • William M Gallagher
  • John Crown
  • Samuel Leung
  • Yemin Wang
  • Steve E Kalloger
  • Britta Stordal
  • Fan Zhang
  • Michael S Anglesio
  • Blake Gilks
  • Colin Clarke
  • Sarah Finlayson
  • Eric Jonasch
  • Pheroze Tamboli
  • Dimitra Tsavachidou
  • J Crown
  • Lei Deng
  • Lajos Pusztai
  • Aysegul Sahin
  • Anne Lise Borresen-Dale
  • Jens Overgaard
  • Sam Aparicio
  • Funda Meric-Bernstam
  • Jan Alsner
  • Simen Myhre
  • Powel Brown
  • Gabriel N Hortobagyi
  • Kevin R Coombes
  • W Fraser Symmans
  • Corey Speers
  • Angela Sanguino
  • Rebecca L Stone
  • Joe W Gray
  • C Kent Osborne
  • Angelo J Casa
  • Yiqun Zhang
  • Francois Xavier Claret
  • Gabriel Lopez-Berestein
  • Powell H Brown
  • Rachel Schiff
  • Juliana Maria Benito
  • Ana Maria Gonzalez-Angulo
  • Cristian Rodriguez-Aguayo
  • Hee Dong Han
  • Xiaoyong Fu
  • Alpa M Nick
  • Arturo Chavez-Reyes
  • William Bornmann
  • Zhengong Peng
  • Adrian V Lee
  • Anil K Sood
  • Susan G Hilsenbeck
  • Yvonne G Lin
  • Lingegowda Mangala
  • Hye Sun Kim

Detail Information

Publications8

  1. pmc OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets
    Stephen F Madden
    Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
    Mol Cancer 13:241. 2014
    ..There is a paucity of robust molecular markers that are independent of and complementary to clinical parameters such as disease stage and tumour grade...
  2. pmc A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation
    Kimberly C Wiegand
    Department of Surgical Oncology, British Columbia, Cancer Agency, Vancouver, BC, Canada
    BMC Cancer 14:120. 2014
    ..We studied the influence of histological subtype on protein expression with reverse phase protein array (RPPA) and assessed proteomic changes associated with ARID1A mutation/BAF250a expression in EC and CCC...
  3. pmc Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
    M S N Mohd Sharial
    Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland
    Ann Oncol 23:3007-16. 2012
    ..HER2-targeted therapy has substantially improved outcomes in patients with HER2-positive breast cancer. However, both de novo and acquired resistance are observed...
  4. pmc An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays
    Huifang Guo
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Proteome Sci 10:56. 2012
    ..abstract:..
  5. pmc Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
    ..abstract:..
  6. pmc Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
    Chad J Creighton
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Breast Cancer Res 12:R40. 2010
    ..We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype...
  7. pmc Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer
    Bryan T J Hennessy
    Department of Gynecology Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:3570-6. 2010
    ..3%. It is important to determine the frequency of somatic BRCA(1/2) changes, given the sensitivity of BRCA-mutated cancers to poly (ADP ribose) polymerase-1 (PARP1) inhibitors and platinum analogs...
  8. pmc c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer
    Pablo Vivas-Mejia
    Department of Experimental Therapeutics, Center for RNAi and non coding RNA, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:184-94. 2010
    ..To show the functional, clinical, and biological significance of c-Jun-NH(2)-kinase (JNK)-1 in ovarian carcinoma...